Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Small Cell Lung Carcinoma 146Adenocarcinoma of Lung 71Neoplasms 44Neoplasm Metastasis 34Adenocarcinoma, Bronchiolo-Alveolar 30Colorectal Neoplasms 25Ovarian Neoplasms 24Carcinoma 24Lung Diseases 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Breast Neoplasms 17Mesothelioma 16Thoracic Neoplasms 15Respiratory Tract Neoplasms 15Mesothelioma, Malignant 15Pancreatic Neoplasms 13NSCLC 13Endometrial Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Bronchogenic 12Adenocarcinoma 12Melanoma 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Brain Neoplasms 10Respiratory Tract Diseases 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9

Interventions

Pemetrexed 1Paclitaxel 1One-Lung Ventilation 1NOV 002 1Carboplatin 1Bevacizumab 1Anesthesia, General 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pericardial Effusion × Carboplatin × Thoracic × Clear all
NCT00347412 2022-07-25

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Cellectar Biosciences, Inc.

Phase 3 Completed
903 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Pericardial Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡